[go: up one dir, main page]

SG10201503257WA - ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY - Google Patents

ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Info

Publication number
SG10201503257WA
SG10201503257WA SG10201503257WA SG10201503257WA SG10201503257WA SG 10201503257W A SG10201503257W A SG 10201503257WA SG 10201503257W A SG10201503257W A SG 10201503257WA SG 10201503257W A SG10201503257W A SG 10201503257WA SG 10201503257W A SG10201503257W A SG 10201503257WA
Authority
SG
Singapore
Prior art keywords
antibody
protein tyrosine
type protein
tyrosine phosphatase
human receptor
Prior art date
Application number
SG10201503257WA
Inventor
Tomohide Yamazaki
Jing Zhao
Koji Ishida
Yasue Shibata
Minkwon Cho
Mayuki Endo
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of SG10201503257WA publication Critical patent/SG10201503257WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
SG10201503257WA 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY SG10201503257WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011101752 2011-04-28

Publications (1)

Publication Number Publication Date
SG10201503257WA true SG10201503257WA (en) 2015-06-29

Family

ID=46147004

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202108240VA SG10202108240VA (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
SG10201503257WA SG10201503257WA (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
SG2013079066A SG194614A1 (en) 2011-04-28 2012-04-27 Anti-human receptor-type protein tyrosine phosphatase # antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202108240VA SG10202108240VA (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013079066A SG194614A1 (en) 2011-04-28 2012-04-27 Anti-human receptor-type protein tyrosine phosphatase # antibody

Country Status (16)

Country Link
US (2) US9803026B2 (en)
EP (2) EP2702412B1 (en)
JP (2) JP6001557B2 (en)
KR (1) KR101873614B1 (en)
CN (1) CN103703372B (en)
AU (2) AU2012248158C1 (en)
CA (1) CA2834243C (en)
ES (2) ES2788183T3 (en)
HU (2) HUE054211T2 (en)
IL (1) IL229127A (en)
MX (1) MX352599B (en)
PL (2) PL2702412T3 (en)
PT (2) PT3232202T (en)
RU (2) RU2013152816A (en)
SG (3) SG10202108240VA (en)
WO (1) WO2012148003A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008270972B2 (en) 2007-07-02 2013-10-24 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2012148003A1 (en) * 2011-04-28 2012-11-01 Sbi Biotech Co., Ltd. ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
US20150175979A1 (en) * 2012-07-23 2015-06-25 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
US11160873B2 (en) * 2014-02-04 2021-11-02 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
US10023653B2 (en) * 2014-02-04 2018-07-17 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
CN107002114A (en) * 2014-12-18 2017-08-01 豪夫迈·罗氏有限公司 Assay and method for determining cdc eliciting antibodies
KR20190132665A (en) * 2017-03-23 2019-11-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Anti-C5a Antibodies and Uses thereof
JP2020514394A (en) * 2017-03-24 2020-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Proteoglycan irregularity in abnormal fibroblasts and therapies based on it
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
CN112770723B (en) 2018-07-25 2024-08-02 阿克罗斯生物科学公司 CLDN 18.2-specific monoclonal antibodies and methods of use thereof
AU2020357889A1 (en) * 2019-10-04 2022-03-24 Albert Einstein College Of Medicine KIR3DL3 is an inhibitory receptor of the immune system and uses thereof
WO2023010132A1 (en) * 2021-07-30 2023-02-02 The Regents Of The University Of California Ptprs in autoimmunity
CN114426582B (en) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 Nerve specific enolase monoclonal antibody and preparation method and application thereof
CN116041526B (en) * 2022-11-14 2023-09-29 华中农业大学 Mouse anti-grass carp IgT monoclonal antibody, preparation method and application thereof
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
WO2024186740A2 (en) * 2023-03-03 2024-09-12 Case Western Reserve University Cell adhesion molecule targeted immunotherapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721352A4 (en) 1993-10-01 1998-07-01 Univ New York Novel receptor-type phosphotyrosine phosphatase-sigma
WO2004013325A1 (en) 2002-08-01 2004-02-12 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
CN1761682A (en) * 2003-03-14 2006-04-19 大正制药株式会社 Monoclonal antibody and hybridoma producing the same
CA2561073C (en) 2004-03-27 2014-01-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007041317A2 (en) 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2009003274A1 (en) * 2007-06-29 2009-01-08 The Hospital For Sick Children Susceptibility gene for inflammatory bowel disease
CA2743464A1 (en) 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2011022462A2 (en) * 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
EP2531859A4 (en) * 2010-02-02 2013-07-31 Jolla Inst Allergy Immunolog COMPOSITIONS AND METHODS FOR MODULATION OF RECEPTOR TYROSINE KINASE PROTEINS
WO2012148003A1 (en) * 2011-04-28 2012-11-01 Sbi Biotech Co., Ltd. ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Also Published As

Publication number Publication date
CA2834243C (en) 2019-08-27
US10730955B2 (en) 2020-08-04
RU2013152816A (en) 2015-06-10
IL229127A (en) 2017-11-30
JP6001557B2 (en) 2016-10-05
US9803026B2 (en) 2017-10-31
CA2834243A1 (en) 2012-11-01
EP2702412B1 (en) 2017-07-26
US20140127223A1 (en) 2014-05-08
PT3232202T (en) 2020-05-22
RU2017118262A3 (en) 2018-11-02
AU2016262677A1 (en) 2016-12-08
JP2017048183A (en) 2017-03-09
US20180155446A1 (en) 2018-06-07
SG10202108240VA (en) 2021-09-29
SG194614A1 (en) 2013-12-30
MX2013012393A (en) 2014-04-30
ES2788183T3 (en) 2020-10-20
AU2016262677B2 (en) 2018-08-30
JP6412072B2 (en) 2018-10-24
EP3232202A1 (en) 2017-10-18
PT2702412T (en) 2017-11-02
HUE054211T2 (en) 2021-08-30
HUE034752T2 (en) 2018-02-28
CN103703372A (en) 2014-04-02
EP2702412A1 (en) 2014-03-05
JP2014524733A (en) 2014-09-25
MX352599B (en) 2017-11-30
KR20140033024A (en) 2014-03-17
RU2715642C2 (en) 2020-03-02
IL229127A0 (en) 2013-12-31
PL2702412T3 (en) 2018-01-31
WO2012148003A1 (en) 2012-11-01
RU2017118262A (en) 2018-11-02
ES2638088T3 (en) 2017-10-18
BR112013027631A2 (en) 2022-01-04
KR101873614B1 (en) 2018-07-02
CN103703372B (en) 2018-01-26
EP3232202B1 (en) 2020-02-19
AU2012248158C1 (en) 2017-02-02
AU2012248158B2 (en) 2016-09-08
AU2012248158A1 (en) 2014-01-30
PL3232202T3 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
IL229127A (en) Anti-human receptor-type protein tyrosine phosphatase σ antibody
IL265865A (en) Antibody and protein formulations
IL259826A (en) Anti-alphabetatcr antibody
IL234237B (en) Methods for obtaining ph-sensitive antigen-binding proteins
ZA201400768B (en) Interleukin-31 monoclonal antibody
HUE036663T2 (en) Preparation for anti-alpha4beta7 antibody
HUE036664T2 (en) Preparation for anti-alpha4beta7 antibody
ZA201307983B (en) Anti-b7-h3 antibody
EP2693951A4 (en) PICTURE ANALYSIS FOR SPECIFIC OBJECTS
TWI563004B (en) Anti-hxcr1 antibody
SG10201705841YA (en) Monoclonal antibody against muramyl peptides